These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 8772805)

  • 1. Prevention and treatment of aluminum toxicity including chelation therapy: status and research needs.
    Yokel RA; Ackrill P; Burgess E; Day JP; Domingo JL; Flaten TP; Savory J
    J Toxicol Environ Health; 1996 Aug; 48(6):667-83. PubMed ID: 8772805
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The 3-hydroxypyridin-4-ones more effectively chelate aluminum in a rabbit model of aluminum intoxication than does desferrioxamine.
    Yokel RA; Meurer KA; Skinner TL; Fredenburg AM
    Drug Metab Dispos; 1996 Jan; 24(1):105-11. PubMed ID: 8825197
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Short-term oral 3-hydroxypyridin-4-one dosing increases aluminum excretion and partially reverses aluminum-induced toxicity in the rabbit independent of chelator lipophilicity.
    Yokel RA; Meurer KA; Hong CB; Dickey KM; Skinner TL; Fredenburg AM
    Drug Metab Dispos; 1997 Feb; 25(2):182-90. PubMed ID: 9029049
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aluminum chelation: chemistry, clinical, and experimental studies and the search for alternatives to desferrioxamine.
    Yokel RA
    J Toxicol Environ Health; 1994 Feb; 41(2):131-74. PubMed ID: 8301696
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of potential aluminum chelators in vitro by aluminum solubilization ability, aluminum mobilization from transferrin and the octanol/aqueous distribution of the chelators and their complexes with aluminum.
    Yokel RA; Datta AK; Jackson EG
    J Pharmacol Exp Ther; 1991 Apr; 257(1):100-6. PubMed ID: 2019981
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reversal by desferrioxamine of tau protein aggregates following two days of treatment in aluminum-induced neurofibrillary degeneration in rabbit: implications for clinical trials in Alzheimer's disease.
    Savory J; Huang Y; Wills MR; Herman MM
    Neurotoxicology; 1998 Apr; 19(2):209-14. PubMed ID: 9553957
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Removal of trace metals by continuous ambulatory peritoneal dialysis after desferrioxamine B chelation therapy.
    Navarro JA; Granadillo VA; Rodríguez-Iturbe B; García R; Salgado O; Romero RA
    Clin Nephrol; 1991 May; 35(5):213-7. PubMed ID: 1855329
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low-dose (5 mg/kg) desferrioxamine treatment in acutely aluminium-intoxicated haemodialysis patients using two drug administration schedules.
    Barata JD; D'Haese PC; Pires C; Lamberts LV; Simões J; De Broe ME
    Nephrol Dial Transplant; 1996 Jan; 11(1):125-32. PubMed ID: 8649620
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Desferrioxamine in the treatment of aluminum overload.
    Ackrill P; Day JP
    Clin Nephrol; 1985; 24 Suppl 1():S94-7. PubMed ID: 3842106
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Aluminum poisoning in dialysis patients--diagnosis and therapy].
    Vogelsang U
    Schweiz Rundsch Med Prax; 1994 Jun; 83(24):738-56. PubMed ID: 8023059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chelator-facilitated removal of iron from transferrin: relevance to combined chelation therapy.
    Devanur LD; Evans RW; Evans PJ; Hider RC
    Biochem J; 2008 Jan; 409(2):439-47. PubMed ID: 17919118
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of desferrioxamine on tissue aluminum concentration and bone histology in aluminum-loaded rats with renal failure.
    Verbeelen D; Smeyers-Verbeke J; van Hooff I; de Roy G
    J Trace Elem Electrolytes Health Dis; 1988 Jun; 2(2):67-72. PubMed ID: 2980801
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of the chelator desferrioxamine on aluminum elimination in rabbits.
    Melograna JM; Yokel RA
    Res Commun Chem Pathol Pharmacol; 1983 Jun; 40(3):497-509. PubMed ID: 6622822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and histological results of long-term management of aluminium overloading in uraemic patients with desferrioxamine.
    Canavese C; Pacitti A; Segoloni G; Thea A; D'Amicone M; Stratta P; Rossi P; Sabbioni E; Pietra R; Constantini S
    J Trace Elem Electrolytes Health Dis; 1989 Mar; 3(1):17-23. PubMed ID: 2535315
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Can the controversy of the role of aluminum in Alzheimer's disease be resolved? What are the suggested approaches to this controversy and methodological issues to be considered?
    Savory J; Exley C; Forbes WF; Huang Y; Joshi JG; Kruck T; McLachlan DR; Wakayama I
    J Toxicol Environ Health; 1996 Aug; 48(6):615-35. PubMed ID: 8772802
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Examination of the antiproliferative activity of iron chelators: multiple cellular targets and the different mechanism of action of triapine compared with desferrioxamine and the potent pyridoxal isonicotinoyl hydrazone analogue 311.
    Chaston TB; Lovejoy DB; Watts RN; Richardson DR
    Clin Cancer Res; 2003 Jan; 9(1):402-14. PubMed ID: 12538494
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The causes, diagnosis and treatment of aluminum toxicity in patients with chronic renal failure undergoing dialysis].
    Wang G; Zhu P; Wang S
    Zhonghua Nei Ke Za Zhi; 1996 Jan; 35(1):36-40. PubMed ID: 9275645
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Desferrioxamine and Alzheimer's disease: video home behavior assessment of clinical course and measures of brain aluminum.
    McLachlan DR; Smith WL; Kruck TP
    Ther Drug Monit; 1993 Dec; 15(6):602-7. PubMed ID: 8122302
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of subchronic desferrioxamine infusion on aluminum toxicity in rabbits.
    Melograna JM; Yokel RA
    Res Commun Chem Pathol Pharmacol; 1984 Jun; 44(3):411-22. PubMed ID: 6463364
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined chelation based on glycosyl-mono- and bis-hydroxypyridinones for aluminium mobilization: solution and biodistribution studies.
    Chaves S; Dron PI; Danalache FA; Sacoto D; Gano L; Santos MA
    J Inorg Biochem; 2009 Nov; 103(11):1521-9. PubMed ID: 19748126
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.